Inotiv, Inc. to Report Fiscal 2025 Third Quarter Financial Results and Host Conference Call on Wednesday, August 6, 2025
Inotiv (NASDAQ:NOTV), a leading contract research organization focused on nonclinical and analytical drug discovery services, has scheduled its fiscal 2025 third quarter financial results announcement for August 6, 2025, after market close.
The company will host a conference call at 4:30 PM Eastern Time on the same day to discuss the results. Investors can access the call through domestic (1-800-245-3047) or international (1-203-518-9765) dial-in numbers using Conference ID: INOTIV. A live webcast will be available on the company's investor relations website, with a replay accessible afterward.
Inotiv (NASDAQ:NOTV), una società leader nel settore della ricerca a contratto specializzata in servizi non clinici e analitici per la scoperta di farmaci, ha programmato l'annuncio dei risultati finanziari del terzo trimestre fiscale 2025 per il 6 agosto 2025, dopo la chiusura del mercato.
La società terrà una conference call alle 16:30 ora della costa orientale dello stesso giorno per discutere i risultati. Gli investitori potranno partecipare alla chiamata tramite i numeri telefonici nazionali (1-800-245-3047) o internazionali (1-203-518-9765) utilizzando l'ID conferenza: INOTIV. Sarà disponibile una diretta streaming sul sito web delle relazioni con gli investitori dell'azienda, con la possibilità di riascoltare la registrazione successivamente.
Inotiv (NASDAQ:NOTV), una organización líder en investigación por contrato enfocada en servicios no clínicos y analíticos para el descubrimiento de fármacos, ha programado el anuncio de sus resultados financieros del tercer trimestre fiscal 2025 para el 6 de agosto de 2025, después del cierre del mercado.
La compañía realizará una conferencia telefónica a las 4:30 PM hora del Este el mismo día para discutir los resultados. Los inversores podrán acceder a la llamada mediante los números nacionales (1-800-245-3047) o internacionales (1-203-518-9765) usando el ID de conferencia: INOTIV. Habrá una transmisión en vivo disponible en el sitio web de relaciones con inversionistas de la compañía, con una repetición accesible posteriormente.
Inotiv (NASDAQ:NOTV)는 비임상 및 분석적 신약 개발 서비스를 전문으로 하는 선도적 계약 연구 기관으로, 2025 회계연도 3분기 재무 결과 발표를 2025년 8월 6일 시장 마감 후에 예정하고 있습니다.
회사는 같은 날 동부 표준시 오후 4시 30분에 컨퍼런스 콜을 개최하여 결과를 논의할 예정입니다. 투자자들은 국내 전화번호(1-800-245-3047) 또는 국제 전화번호(1-203-518-9765)를 통해 컨퍼런스 ID: INOTIV를 사용하여 콜에 접속할 수 있습니다. 회사 투자자 관계 웹사이트에서 생중계가 제공되며, 이후 재청취도 가능합니다.
Inotiv (NASDAQ:NOTV), une organisation de recherche sous contrat de premier plan spécialisée dans les services non cliniques et analytiques pour la découverte de médicaments, a programmé l'annonce de ses résultats financiers du troisième trimestre fiscal 2025 pour le 6 août 2025, après la clôture du marché.
L'entreprise tiendra une conférence téléphonique à 16h30 heure de l'Est le même jour pour discuter des résultats. Les investisseurs pourront accéder à l'appel via les numéros nationaux (1-800-245-3047) ou internationaux (1-203-518-9765) en utilisant l'ID de conférence : INOTIV. Un webcast en direct sera disponible sur le site des relations investisseurs de l'entreprise, avec une rediffusion accessible par la suite.
Inotiv (NASDAQ:NOTV), ein führendes Auftragsforschungsunternehmen, das sich auf nichtklinische und analytische Dienstleistungen in der Arzneimittelentwicklung spezialisiert hat, hat die Bekanntgabe der Finanzergebnisse für das dritte Quartal des Geschäftsjahres 2025 für den 6. August 2025 nach Börsenschluss angesetzt.
Das Unternehmen wird am selben Tag um 16:30 Uhr Eastern Time eine Telefonkonferenz abhalten, um die Ergebnisse zu besprechen. Investoren können über nationale (1-800-245-3047) oder internationale (1-203-518-9765) Einwahlnummern mit der Konferenz-ID: INOTIV teilnehmen. Ein Live-Webcast wird auf der Investor-Relations-Website des Unternehmens verfügbar sein, mit anschließender Wiedergabemöglichkeit.
- None.
- None.
WEST LAFAYETTE, Ind., July 23, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2025 third quarter ended June 30, 2025, on Wednesday, August 6, 2025, after the close of the stock market. The Company will host a conference call that same day at 4:30 p.m. Eastern Time to discuss the results.
Interested parties may participate in the call by dialing:
- 1-800-245-3047 (Domestic)
- 1-203-518-9765 (International)
- INOTIV (Conference ID)
The live conference call webcast will be accessible in the Investors section of the Company’s web site and directly via the following link:
https://viavid.webcasts.com/starthere.jsp?ei=1725515&tp_key=690c604cf0
For those who cannot listen to the live broadcast, an online replay will be available in the Investors section of Inotiv’s web site at: https://ir.inotiv.com/overview/default.aspx.
About Inotiv
Inotiv, Inc. is a leading contract research organization dedicated to providing nonclinical and analytical drug discovery and development services and research models and related products and services. The Company’s products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development, all while increasing efficiency, improving data, and reducing the cost of taking new drugs and medical devices to market. Inotiv is committed to supporting discovery and development objectives as well as helping researchers realize the full potential of their critical research and development projects, all while working together to build a healthier and safer world. Further information about Inotiv can be found here: https://www.inotiv.com/.
This release may contain forward-looking statements that are subject to risks and uncertainties including, but not limited to, risks and uncertainties related to the impact of recent events related to non-human primate matters on the Company’s business, operations, results, financial condition, cash flows, and assets, the Company’s ability to comply with covenants under its credit agreement, compliance with the Resolution and Plea Agreements with the DOJ and the expected impacts on the Company related to the compliance plan, compliance monitor, and the expected financial commitments, changes in the market and demand for the Company’s products and services, the development, marketing and sales of products and services, changes in technology, industry and regulatory standards, the timing of acquisitions and the successful closing, integration and business and financial impact thereof, governmental regulations, inspections and investigations, claims and litigation against or involving the Company, its business and/or its industry, the impact of site closures and consolidations, expansion and related efforts, and various other market and operating risks, including those detailed in the Company's filings with the U.S. Securities and Exchange Commission.
| Company Contact | Investor Relations | |
| Inotiv, Inc. | LifeSci Advisors | |
| Beth A. Taylor, Chief Financial Officer | Steve Halper | |
| (765) 497-8381 | (646) 876-6455 | |
| beth.taylor@inotiv.com | shalper@lifesciadvisors.com |
FAQ
When will Inotiv (NOTV) report its Q3 2025 earnings?
How can investors join Inotiv's Q3 2025 earnings call?
What time is Inotiv's Q3 2025 earnings conference call?
Where can I find the replay of Inotiv's Q3 2025 earnings call?
